Targeting Mycobacterium tuberculosis Biotin Protein Ligase (MtBPL) with Nucleoside-Based Bisubstrate Adenylation Inhibitors

Matthew R. Bockman, Alvin S. Kalinda, Riccardo Petrelli, Teresa De La Mora-Rey, Divya Tiwari, Feng Liu, Surendra Dawadi, Madhumitha Nandakumar, Kyu Y. Rhee, Dirk Schnappinger, Barry C. Finzel, Courtney C. Aldrich

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Mycobacterium tuberculosis (Mtb), responsible for both latent and symptomatic tuberculosis (TB), remains the second leading cause of mortality among infectious diseases worldwide. Mycobacterial biotin protein ligase (MtBPL) is an essential enzyme in Mtb and regulates lipid metabolism through the post-translational biotinylation of acyl coenzyme A carboxylases. We report the synthesis and evaluation of a systematic series of potent nucleoside-based inhibitors of MtBPL that contain modifications to the ribofuranosyl ring of the nucleoside. All compounds were characterized by isothermal titration calorimetry (ITC) and shown to bind potently with KDs ≤ 2 nM. Additionally, we obtained high-resolution cocrystal structures for a majority of the compounds. Despite fairly uniform biochemical potency, the whole-cell Mtb activity varied greatly with minimum inhibitory concentrations (MIC) ranging from 0.78 to >100 μM. Cellular accumulation studies showed a nearly 10-fold enhancement in accumulation of a C-2′-α analogue over the corresponding C-2′-β analogue, consistent with their differential whole-cell activity.

Original languageEnglish (US)
Pages (from-to)7349-7369
Number of pages21
JournalJournal of medicinal chemistry
Issue number18
StatePublished - Sep 24 2015

Bibliographical note

Publisher Copyright:
© 2015 American Chemical Society.


Dive into the research topics of 'Targeting Mycobacterium tuberculosis Biotin Protein Ligase (MtBPL) with Nucleoside-Based Bisubstrate Adenylation Inhibitors'. Together they form a unique fingerprint.

Cite this